A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond.
Marcus S NoelSemmie KimMarion L HartleySteve WongVincent J PicozziHarry StaszewskiDae Won KimJan M Van TornoutPhilip Agop PhilipVincent ChungAllyson J OceanAndrea Wang-GillamPublished in: Cancer medicine (2022)
gov Identifier: NCT03512756.